Evidence map›Paper›PMID 35267490›Full record

ArticleCancers2022

Lipid Status of A2780 Ovarian Cancer Cells after Treatment with Ruthenium Complex Modified with Carbon Dot Nanocarriers: A Multimodal SR-FTIR Spectroscopy and MALDI TOF Mass Spectrometry Study.

Maja D Nešić, Tanja Dučić, Manuel Algarra, Iva Popović, Milutin Stepić, Mara Gonçalves, Marijana Petković

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Maja D NešićCenter for Light-Based Research and Technologies COHERENCE, Department of Atomic Physics, Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-9167-6553
Tanja DučićALBA-CELLS Synchrotron, MIRAS Beamline, 08290 Cerdanyola del Vallès, Spain.ORCID 0000-0003-2389-3887
Manuel AlgarraINAMAT2-Institute for Advanced Materials and Mathematics, Department of Science, Public University of Navarre, Campus de Arrosadia, 31006 Pamplona, Spain.ORCID 0000-0003-2410-8430
Iva PopovićCenter for Light-Based Research and Technologies COHERENCE, Department of Atomic Physics, Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia.
Milutin StepićCenter for Light-Based Research and Technologies COHERENCE, Department of Atomic Physics, Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia.
Mara GonçalvesCQM-Centro de Química da Madeira, Universidade da Madeira, 9020-105 Funchal, Portugal.ORCID 0000-0002-0332-3548
Marijana PetkovićCenter for Light-Based Research and Technologies COHERENCE, Department of Atomic Physics, Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-8354-995X
University of Belgrade · RSALBA Synchrotron (Spain) · ESUniversidade da Madeira · PTUniversidad Publica de Navarra · ES

Funding

ALBA Synchrotron (Spain) experiment Nr. 2019093770ARDITI-Agência Regional para o Desenvolvimento da InvestigaçãoTecnologia e Inovação M1420-01-0145-FEDER-000005-CQM+Ministry of Education, Science and Technological Development of the Republic of Serbia 451-03-68/2020-14/200017
6 · The paper itself

Abstract

In the last decade, targeting membrane lipids in cancer cells has been a promising approach that deserves attention in the field of anticancer drug development. To get a comprehensive understanding of the effect of the drug [Ru(η

Indexed as

anticancer Ru metallodrugcarbon dotsdrug nanocarrierslipidsMALDI TOF MSN-doped carbon dotsSR-FTIR spectroscopy

Identifiers

PMID35267490
PMCPMC8909423
OpenAlexW4214485321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.